Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)

NCT07033689 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DEVICE: Suizenji (an ultrasound-guided HIFU therapy system)
DRUG: Nal-IRI/FL
DRUG: mFOLFIRINOX adjuvant chemotherapy
DRUG: Gem/nab-PTX

Sponsor

SONIRE Therapeutics Inc.